Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2005-05-24
2005-05-24
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
active
06897243
ABSTRACT:
The present invention relates to methods of treating an individual with diabetes mellitus by administering to said individual an effective amount of copper chelators, hydrazine compounds, and/or substrate analogues. The invention also relates to methods of treating an individual with diabetes mellitus by lessening fructosamine odixase activity in said individual. Provided within is disclosure pertaining to treatment, pharmaceutical compositions, dosage ranges, and uses of fructosamine oxidase enzyme inhibitors to lessen fructosamine oxidase activity.
REFERENCES:
patent: 4374829 (1983-02-01), Harris et al.
patent: 4410541 (1983-10-01), Kamimae et al.
patent: 4758583 (1988-07-01), Cerami et al.
patent: 4866090 (1989-09-01), Hoffman et al.
patent: 4952568 (1990-08-01), Sawai et al.
patent: 5077313 (1991-12-01), Lubec
patent: 5128360 (1992-07-01), Cerami et al.
patent: 5246970 (1993-09-01), Williamson et al.
patent: 5387109 (1995-02-01), Ishikawa et al.
patent: 5852009 (1998-12-01), Cerami et al.
patent: 6348465 (2002-02-01), Baker
patent: 6610693 (2003-08-01), Baker
patent: 3091889 (1989-09-01), None
patent: 8093694 (1995-05-01), None
patent: 1447095 (1995-07-01), None
patent: 4134996 (1996-05-01), None
patent: 3217071 (1983-11-01), None
patent: 0 426 066 (1991-05-01), None
patent: 0 576 838 (1994-01-01), None
patent: 2192789 (1988-01-01), None
patent: 2192790 (1988-01-01), None
patent: 57-144215 (1982-09-01), None
patent: WO 8504169 (1985-09-01), None
patent: WO 8705505 (1987-09-01), None
patent: WO 9511690 (1995-05-01), None
patent: WO 9517900 (1995-07-01), None
patent: WO 9612483 (1996-05-01), None
patent: WO 9939712 (1999-08-01), None
patent: WO 0018392 (2000-04-01), None
patent: WO 00.18392 (2000-04-01), None
patent: WO 0018891 (2000-04-01), None
Allen, K. G. D. et al. (Jan. 1987). “Tetramine Cupruretic Agents: A Comparison in Dogs,”Am. J. Vet. Res.48(1):28-30.
Borthwick, T. R. et al. (Apr. 1980). “Copper Chelating Agents: A Comparison of Cupruretic Responses to Various Tetramines and D-Penicillamine,”J. Lab. Clin. Med.95(4):575-580.
Cameron, N. E. and Cotter, M. A. (Aug. 1995). “Neurovascular Dysfunction in Diabetic Rats. Potential Contribution of Autoxidation and Free Radicals Examined Using Transition Metal Chelating Agents,”J. Clin. Invest.96(2):1159-1163.
Cameron, N.E. et al. (1995). “Ciliary Neuronotrophic Factor Improves Nerve Conduction and Regeneration in Experimental Diabetes,”Diabetologia38(Suppl. 1):A233 Abstract.
Cohen, N. L. et al. (1983). “The Effect of Copper Chelating Drugs on Liver Iron Mobilization in the Adult Rat,”Biochemical and Biophysical Research Communications113(1):127-134.
Dwivedi, R. S. et al. (1978). “The Effect of Triethylene Tetramine Upon the Selective Removal of Nickel (II), Iron (II), Manganese (II) and Tin (II) in Rats,”Chemosphere11:925-932.
Iseki, K. et al. (1992). “Comparison of Disposition Behavior and De-Coppering Effect of Triethylenetetramine in Animal Model for Wilson's Disease (Long-Evans Cinnamon Rat) with Normal Wistar Rat,”Biopharmaceutics&Drug Deposition13:273-283.
Keegan, A. et al. (1996). “Transition Metal Chelators and Anti-Oxidants Prevent the Development of Defective Endothelium-Dependent Relaxation in Aortas from Diabetic Rats,”Diabetic Medicine13(Suppl. 1):S17 Abstract.
Keegan, A. et al. (Sep. 27, 1999). “Effects of Chelator Treatment on Aorta and Corpus Cavernosum From Diabetic Rats,”Free Radical Biology&Medicine27(5-6):536-543.
Appelbaum et al., “The Protective Role of Neocuproine Against Cardiac Damage in Isolated Perfused Rat Hearts”,Free Radical Biology&Medicine,vol. 8, pp. 133-143, 1990; Pergamon Press USA.
Beshgetoor et al., “Clinical conditions altering cooper metabolism in humans”, Am J Clin Nutr 1998; 67 (suppl):1017S-21S.
Bingham et al., “Characterization of intracellular copper pools in rat hepatocytes using the chelator diamsar”, Am. J. Physiol. 272 (Gastrointest. Liver Physiol. 35): G1400-G1407, 1997.
Brownlee et al., “Aminoguanidine Prevents Diabetes-Induced Arterial Wall Protein Cross-Linking”, Science, New Series, vol. 232, No. 4758 (Jun. 27, 1986), 1629-1632.
Bryszewska et al., “Oxidative Processes in Red Blood Cells from Normal and Diabetic Individuals”,Biochemistry and Molecular Biology International,vol. 37, No. 2, 345-354, Oct. 1995.
Chang et al., “Increased Collagen Cross-Linkages in Experimental Diabetes Reversal by β-Aminopropionitrile and D-Penicillamine”, Diabetes, vol. 29, Oct. 1980, 778-781.
Cooper, “The Action of Mebanazine, a Mono Amine Oxidase Inhibitor Antidepressant Drug in Diabetes”, Int. J. Neurophyschiatry, 4:342-5(1966).
Dubois et al., “Triethylene Tetramine Dihydrochloride in Wilson's Disease,” The Lancet, Oct. 1970.
Ekblom, “Potential Therapeutic Value of Drugs Inhibiting Semicarbazide-Sensitive Amine Oxidase: Vascular Cytoprotection in Diabetes Mellitus”, Pharmacological Research, vol. 37, No 2, 1998.
Elling, “Penicillamine, Captopril, and Hypoglycemia”, Annals of Internal Medicine, vol. 103, No. 4, Oct. 1985.
Hoffken et al., “Excretion of Zinc in Diabetics Receiving Penicillamine”, Z Klin Chem Klin Biochem. Jan. 7, 1969; (1):4-7.
Leinonen et al., “Susceptibility of LDL to oxidation is not associated with the presence of coronary heart disease or renal dysfunction in NIDDM patients”, Clinica Chimica Acta 275 (1998) 163-174.
McArdle et al., “Effect of chelators on copper metabolism and cooper pools in mouse hepatocytes,” Am. J. Physiol. 256 (Gastrointest. Liver Physiol. 19): G667-G672, 1989.
Norton et al., “Amioguanidine Prevents the Decreased Myocardial Compliance Produced by Streptozotocin-Induced Diabetes Mellitus in Rats”, Circulation. 1996;93:1905-1912.
Ou et al., Thioctic (Lipoic) Acid: ATherapeutic Metal-Chelating Antioxidant?, Biochemical Pharmacology, vol. 50, No. 1, pp.123-126. (1995).
Pucheu, et al., “Effect of Iron Overload in the Isolated Ischemic and Reperfused Rat Heart,”,Cardiovascular Drugs and Therapy,1993; 7:701-711.
Rogers et al., “Hydrazine Stress in the Diabetic: Ornithine Decarboxylase Activity”, Biochemical Medicine and Metabolic Biology, 40, 46-49 (1988).
Salonen et al., Serum Copper and the Risk of Acute Myocardial Infarction: A Prospective Population Study in Men in Eastern Finland, Am. J. Epidemiol, 1991; 134: 268-76.
Saunders, “The Effects of Excess Renal Copper on Kidney Function in the Diabetic Rat”, Research Communications in Chemical Pathology and Pharmacology, vol. 52, No. 1, Apr. 1986, 45-49.
Sugimoto et al., “Effects of Aminoguanidine on Structural Alterations of Microvessels in Peripheral Nerve of Streptozotocin Diabetic Rats”, Microvascular Research 53, 105-112 (1997).
Tessier et al., “Effect of pH, phosphate and copper on the interaction of glucose with albumin”, Glyconjugate Journal 15, 571-574 (1998), U.K.
Vesely et al., “New Strategies in the Prevention and Management of Diabetes and Its Complications,” Online Journal, Jacksonville Medicine: May 1997. http://www.onlinejournal.com.
Walter et al, “Copper, Zinc, Manganese, and Magnesium Status and Complications of Diabetes Mellitus”, Diabetes Care, vol. 14, No. 11, Nov. 1991.
Wolff et al., “Aminoguanidine Is an Isoform-Selective, Mechanism-Based Inactivator of Nitric Oxide Synthase”, Archives of Biochemistry and Biophysics, vol. 316, No. 1, Jan. 10, pp. 290-301, 1995.
Wolff et al., “Inactivation of Nitric Oxide Synthase by Substituted Aminoguanidines and Aminoisothioureas1”, JPET 283:265-273, 1997.
Wolff, “Diabetes Mellitus and Free Radicals”,The British Council(1993), vol. 49, No. 3 pp. 642-652.
Yagihashi et al., “Effect of Aminoguanidine on Functional and Structural Abnormalities in peripheral Nerve of STZ-In
Baker John Richard
Cooper Garth J. S.
Buchanan Ingersoll P.C.
Henley III Raymond J.
Protemix Corporation Limited
LandOfFree
Fructosamine oxidase: antagonists and inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fructosamine oxidase: antagonists and inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fructosamine oxidase: antagonists and inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3380235